These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15449965)

  • 1. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy.
    Garattini L; Brunetti M; Salvioni F; Barosi M
    Pharmacoeconomics; 1997 Jul; 12(1):67-75. PubMed ID: 10169388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
    Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
    Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.
    Hendry BM; Viberti GC; Hummel S; Bagust A; Piercy J
    QJM; 1997 Apr; 90(4):277-82. PubMed ID: 9307762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation.
    Kiberd BA; Jindal KK
    Am J Kidney Dis; 1998 Jan; 31(1):49-54. PubMed ID: 9428451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
    Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
    Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation.
    Kiberd BA; Jindal KK
    BMJ; 1995 Dec; 311(7020):1595-9. PubMed ID: 8555801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
    St Charles M; Lynch P; Graham C; Minshall ME
    Value Health; 2009; 12(5):674-86. PubMed ID: 19171006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.
    Adarkwah CC; Gandjour A; Akkerman M; Evers SM
    PLoS One; 2011; 6(10):e26139. PubMed ID: 22022539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness.
    Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B
    Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.